Transcriptome-wide RNA modification profiling via Adduct-IP
通过 Adduct-IP 进行全转录组 RNA 修饰分析
基本信息
- 批准号:8773425
- 负责人:
- 金额:$ 22.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-15 至 2016-05-31
- 项目状态:已结题
- 来源:
- 关键词:5 fluorouridineAzacitidineBiologicalBiological ProcessBrainCancer cell lineCatalogingCatalogsCell LineCellsClinicalComplementComplementary DNAComplexCytosineDataDefectDetectionDevelopmentDiseaseDyskeratosis CongenitaEnzymesEventFoundationsFunctional RNAGene Expression ProfileGenesGeneticGenomeGrowthHela CellsHereditary DiseaseHumanImmunoprecipitationInfertilityLinkMalignant NeoplasmsMental RetardationMessenger RNAMethylationMethyltransferaseModificationNucleotidesPathogenesisPathway interactionsPositioning AttributePost-Transcriptional RNA ProcessingPrecipitationProcessPropertyProteinsPseudouridineRNARibosomal RNARoleSiteSmall Nuclear RibonucleoproteinsStressStructureSyndromeSystemTechniquesTechnologyTestingTransfer RNAUridineValidationVariantadductbasebisulfitecancer cellembryonic stem cellgain of functionhuman embryonic stem cellimprovedin vivoinnovationmembermethylomenovelnovel strategiesnucleotide analogpublic health relevanceresearch studyresponsestable cell linetooltumorigenesis
项目摘要
DESCRIPTION (provided by applicant):
Post-transcriptional RNA modifications can impact the sequence, structure and function of RNA molecules. Over 100 distinct modified nucleotides have been characterized so far in RNA, and RNA modifying enzymes comprise a marked proportion of genomes. However, for certain key modifications their full scope, specific enzymes and biological roles are not well understood - due in part to lack of appropriate transcriptome-wide technologies. This is despite the profound clinical implications observed upon loss/gain of function of many RNA modification enzymes, which can confer diverse genetic syndromes, mental retardation, and infertility. We recently developed Aza-IP, a mechanism-based novel technique that greatly enriches the precise direct targets of RNA cytosine methyltransferases (m5C-RMTs). We tested Aza-IP in HeLa cells, and conducted transcriptome-wide target profiling of two important human m5C-RMTs; DNMT2 and NSUN2. Here, in Aim 1 we apply Aza-IP for target profiling of all eight other m5C-RMTs in both HeLa cells and hESCs. In Aim 2, we expand the applicability of the mechanism-based enrichment strategy - which can be generally referred to as 'Adduct-IP' - for target profiling of another important class of RNA modifying enzymes; pseudouridine synthases. Our mechanism-based 'Adduct-IP' approaches involve the in-vivo covalent attachment of the enzyme to its substrate. For Aza-IP, 5-azacytidine is transcriptionally incorporated in place of cytosine within all RNAs, leading to covalent attachment of the proper m5C-RMT at its specific target - which is followed by immuno-precipitation, release and cDNA sequencing. Aza-IP specifically enriches the direct targets of m5C- RMTs, and also generates a clear and penetrant C>G transversion 'signature' exclusively at the exact target cytosine. Importantly Aza-IP captures low copy RNA targets and also rare methylation events, which are under the detection limit of other techniques such as RNA bisulfite sequencing. Here, we aim to expand this technique to discover the targets for the remaining eight known human m5C-RMTs. Beyond m5C-RMTs, pseudouridine synthases are another important class of RNA modifying enzymes that isomerize specific uridines in various RNA species into pseudouridine. Pseudouridine is the most abundant modified nucleotide in RNA and is essential for proper structure and function of rRNAs, tRNAs and snRNAs. Although presence of pseudouridine in other RNA species (ncRNAs and mRNAs) is expected, the field is hampered by lack of tools for transcriptome-wide profiling of this modification which would reveal the scope of this modification. Interestingly, pseudouridine synthases can become irreversibly inhibited (through covalent linkage) by the nucleotide analogue 5-flurourdine through a similar mechanism as of 5-aza-C inhibition of m5C-RMTs. Here we aim to apply the Adduct-IP strategy for transcriptome-wide target profiling of selected pseudouridine synthases (such as DKC1), with significant involvement in a genetic disease (dyskeratosis congenita) and also in cancer.
描述(由申请人提供):
转录后RNA修饰可以影响RNA分子的序列、结构和功能。到目前为止,在RNA中已经表征了超过100种不同的修饰核苷酸,并且RNA修饰酶包含显著比例的基因组。然而,对于某些关键修饰,其全部范围,特定的酶和生物学作用尚未得到很好的理解-部分原因是缺乏适当的全转录组技术。尽管在许多RNA修饰酶的功能丧失/获得后观察到了深刻的临床意义,但这可能导致不同的遗传综合征、智力迟钝和不育。我们最近开发了Aza-IP,这是一种基于机制的新技术,极大地丰富了RNA胞嘧啶甲基转移酶(m5 C-RMTs)的精确直接靶标。我们在HeLa细胞中测试了Aza-IP,并对两种重要的人m5 C-RMT; DNMT 2和NSUN 2进行了转录组范围的靶向分析。在这里,在目的1中,我们应用Aza-IP对HeLa细胞和hESC中的所有八种其他m5 C-RMT进行靶分析。在目标2中,我们扩展了基于机制的富集策略(通常称为“Adduct-IP”)的适用性,用于另一类重要的RNA修饰酶的靶向分析;假尿苷合酶。我们的基于机制的“加合物-IP”方法涉及酶与其底物的体内共价连接。对于Aza-IP,5-氮杂胞苷在转录上掺入所有RNA中的胞嘧啶位置,导致适当的m5 C-RMT共价连接在其特异性靶标上,随后进行免疫沉淀、释放和cDNA测序。Aza-IP特异性地富集m5 C-RMT的直接靶标,并且还仅在确切的靶标胞嘧啶处产生清晰且渗透性的C>G颠换“特征”。重要的是,Aza-IP捕获低拷贝RNA靶标以及罕见的甲基化事件,其低于其他技术如RNA亚硫酸氢盐测序的检测限。在这里,我们的目标是扩展这项技术,以发现其余8个已知的人类m5 C-RMT的目标。除了m5 C-RMT之外,假尿苷二磷酸酶是另一类重要的RNA修饰酶,其将各种RNA物质中的特定尿苷异构化为假尿苷。假尿苷是RNA中最丰富的修饰核苷酸,并且对于rRNA、tRNA和snRNA的适当结构和功能是必需的。尽管预期在其他RNA种类(ncRNA和mRNA)中存在假尿苷,但该领域受到缺乏用于该修饰的转录组范围谱分析的工具的阻碍,该工具将揭示该修饰的范围。有趣的是,假尿苷激酶可以通过与5-aza-C抑制m5 C-RMT相似的机制被核苷酸类似物5-flurourdine不可逆地抑制(通过共价键)。在这里,我们的目标是应用Adduct-IP策略对选定的假尿苷激酶(如DKC 1)进行全转录组靶向分析,这些酶与遗传性疾病(先天性角化不良)和癌症有重要关系。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRADLEY R. CAIRNS其他文献
BRADLEY R. CAIRNS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRADLEY R. CAIRNS', 18)}}的其他基金
Molecular, Epigenetic and Genomic Approaches to Understand Mechanisms of Aging in the Human Testis
通过分子、表观遗传学和基因组方法了解人类睾丸衰老机制
- 批准号:
10265515 - 财政年份:2020
- 资助金额:
$ 22.35万 - 项目类别:
Molecular, Epigenetic and Genomic Approaches to Understand Mechanisms of Aging in the Human Testis
通过分子、表观遗传学和基因组方法了解人类睾丸衰老机制
- 批准号:
10090925 - 财政年份:2020
- 资助金额:
$ 22.35万 - 项目类别:
Molecular, Epigenetic and Genomic Approaches to Understand Mechanisms of Aging in the Human Testis
通过分子、表观遗传学和基因组方法了解人类睾丸衰老机制
- 批准号:
10432077 - 财政年份:2020
- 资助金额:
$ 22.35万 - 项目类别:
Molecular, Epigenetic and Genomic Approaches to Understand Mechanisms of Aging in the Human Testis
通过分子、表观遗传学和基因组方法了解人类睾丸衰老机制
- 批准号:
10646506 - 财政年份:2020
- 资助金额:
$ 22.35万 - 项目类别:
Identifying Epigenetic, Chromatin, and Transcriptomic landscapes to Improve SCNT Development in an Animal Model
识别表观遗传、染色质和转录组景观以改善动物模型中 SCNT 的发展
- 批准号:
10406300 - 财政年份:2019
- 资助金额:
$ 22.35万 - 项目类别:
Identifying Epigenetic, Chromatin, and Transcriptomic landscapes to Improve SCNT Development in an Animal Model
识别表观遗传、染色质和转录组景观以改善动物模型中 SCNT 的发展
- 批准号:
10624437 - 财政年份:2019
- 资助金额:
$ 22.35万 - 项目类别:
Identifying Epigenetic, Chromatin, and Transcriptomic landscapes to Improve SCNT Development in an Animal Model
识别表观遗传、染色质和转录组景观以改善动物模型中 SCNT 的发展
- 批准号:
10005439 - 财政年份:2019
- 资助金额:
$ 22.35万 - 项目类别:
Identifying Epigenetic, Chromatin, and Transcriptomic landscapes to Improve SCNT Development in an Animal Model
识别表观遗传、染色质和转录组景观以改善动物模型中 SCNT 的发展
- 批准号:
10187618 - 财政年份:2019
- 资助金额:
$ 22.35万 - 项目类别:
Identifying Epigenetic, Chromatin, and Transcriptomic landscapes to Improve SCNT Development in an Animal Model
识别表观遗传、染色质和转录组景观以改善动物模型中 SCNT 的发展
- 批准号:
9795100 - 财政年份:2019
- 资助金额:
$ 22.35万 - 项目类别:
Epigenetic Mechanisms Driving Synovial Sarcomagenesis
驱动滑膜肉瘤发生的表观遗传机制
- 批准号:
10090570 - 财政年份:2017
- 资助金额:
$ 22.35万 - 项目类别:
相似国自然基金
CRISPR/Cas9全基因组文库筛选Venetoclax/Azacitidine耐药关键基因及其机制研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Serial monitoring of circulating cell-free tumor DNA as measured by duplex sequencing in older patients with acute myeloid leukemia who receive azacitidine+venetoclax +/- immune checkpoint blockade
通过双重测序对接受阿扎胞苷维奈托克/免疫检查点阻断的老年急性髓系白血病患者的循环游离肿瘤 DNA 进行连续监测
- 批准号:
10337831 - 财政年份:2021
- 资助金额:
$ 22.35万 - 项目类别:
Precision Medicine for Myeloid Malignancies with 5-Azacitidine
5-阿扎胞苷用于骨髓恶性肿瘤的精准医学
- 批准号:
422236 - 财政年份:2020
- 资助金额:
$ 22.35万 - 项目类别:
Fellowship Programs
Precision Medicine for Myeloid Malignancies with 5-Azacitidine
5-阿扎胞苷用于骨髓恶性肿瘤的精准医学
- 批准号:
417283 - 财政年份:2019
- 资助金额:
$ 22.35万 - 项目类别:
Studentship Programs
Beyond Azacitidine: Investigating new therapeutic targets for the treatment of Myelodysplastic Syndrome
超越阿扎胞苷:研究治疗骨髓增生异常综合征的新治疗靶点
- 批准号:
nhmrc : GNT1163815 - 财政年份:2019
- 资助金额:
$ 22.35万 - 项目类别:
Project Grants
Clonal Evolution in Myelodysplasia and Acute Myeloid Leukaemia following Azacitidine
阿扎胞苷后骨髓增生异常和急性髓系白血病的克隆进化
- 批准号:
nhmrc : GNT1128984 - 财政年份:2017
- 资助金额:
$ 22.35万 - 项目类别:
Project Grants
Clonal Evolution in Myelodysplasia and Acute Myeloid Leukaemia following Azacitidine
阿扎胞苷后骨髓增生异常和急性髓系白血病的克隆进化
- 批准号:
nhmrc : 1128984 - 财政年份:2017
- 资助金额:
$ 22.35万 - 项目类别:
Project Grants
Azacitidine耐性機序の解明に基づく新たな急性白血病治療戦略の確立
阐明阿扎胞苷耐药机制建立急性白血病治疗新策略
- 批准号:
25461435 - 财政年份:2013
- 资助金额:
$ 22.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PET Imaging of GVHD and GVL after treatment with Azacitidine
阿扎胞苷治疗后 GVHD 和 GVL 的 PET 成像
- 批准号:
8195498 - 财政年份:2012
- 资助金额:
$ 22.35万 - 项目类别:
Phase II trial of Azacitidine plus Deferasirox in higher risk Myelodysplastic Syndromes (MDS)
阿扎胞苷加地拉罗司治疗高危骨髓增生异常综合征 (MDS) 的 II 期试验
- 批准号:
243003 - 财政年份:2011
- 资助金额:
$ 22.35万 - 项目类别:
Fellowship Programs
PET Imaging of GVHD and GVL after treatment with Azacitidine
阿扎胞苷治疗后 GVHD 和 GVL 的 PET 成像
- 批准号:
8567974 - 财政年份:
- 资助金额:
$ 22.35万 - 项目类别: